US4412988A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hexapeptides
Assignee: Sanofi Aventis France
•
Filing: 1981-10-09
•
Granted: 1983-11-01
•
Expires: 2001-10-09
Abstract
Abstract Novel hexapeptides of the formula Cys--X--Y--D--Lys--Z I wherein X is a sequence selected from the group consisting of Ala--Ala and Glu--His, Y is selected from the group consisting of Cys and Phe and Z is Phe when Y is Cys or Z is Cys when Y is Phe, the two Cys groups in the molecule being joined by a disulfide bridge, and their functional derivatives such as their non-toxic, pharmaceutically acceptable acid addition salts, salts with bases, esters and amides and metallic complexes thereof having an influence on the memory process and their preparation.
Inventors
- 👤 Jean-Claude Gasc
- 👤 Serge Geoffre
- 👤 Michel Hospital
- 👤 Jacques Laurent
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 15:20
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/06; A; A61; A61P; A61P25/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/26; Y10S930/27
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
119 words
A compound selected from the group consisting of hexapeptides of the formula Cys-X-Y-D-Lys-Z I wherein x is a sequence selected from the group consisting of Ala-Ala and Glu-His, Y is selected from the Group consisting of Cys and Phe, Z is Phe when Y is Cys or Z is Cys when Y is Phe, the two Cys groups in the molecule being joined by a disulfide bridge, their non-toxic, pharmaceutically acceptable acid addition salts; their salts of non-toxic, pharmaceutically acceptable bases, their non-toxic, pharmaceutically acceptable esters and their amides and N-alkyl or N,N-dialkyl amides of 1 to 5 carbon atoms and their metallic complexes with a metal selected from the group consisting of cobalt, nickel, copper, iron and zinc.
Claim 2
Dependent Claim
119 words
A compound selected from the group consisting of hexapeptides of the formula Cys-X-Y-D-Lys-Z I wherein x is a sequence selected from the group consisting of Ala-Ala and Glu-His, Y is selected from the Group consisting of Cys and Phe, Z is Phe when Y is Cys or Z is Cys when Y is Phe, the two Cys groups in the molecule being joined by a disulfide bridge, their non-toxic, pharmaceutically acceptable acid addition salts; their salts of non-toxic, pharmaceutically acceptable bases, their non-toxic, pharmaceutically acceptable esters and their amides and N-alkyl or N,N-dialkyl amides of 1 to 5 carbon atoms and their metallic complexes with a metal selected from the group consisting of cobalt, nickel, copper, iron and zinc.
Claim 3
Dependent Claim
11 words
A compound of claim 1 wherein X is the sequence Ala-Ala.
Claim 4
Dependent Claim
11 words
A compound of claim 1 wherein X is the sequence Glu-His.
Claim 5
Dependent Claim
22 words
A compound of claim 1 which is selected from the group consisting of the cyclic disulfide (1→6) of N-(cysteinylalanylalanylphenylalanyl-D-lysyl)-cysteine and its acetate.
Claim 6
Dependent Claim
22 words
A compound of claim 1 which is selected from the group consisting of the cyclic disulfide (1→4) of N-(cysteinylalanylalanylcysteinyl-D-lysyl)-phenylalanine and its acetate.
Claim 7
Dependent Claim
13 words
A compound of claim 1 which is the cyclic disulfide (1→4) of (N-cysteinylglutamylhistidinylcysteinyl-D-lysyl)-phenylalanine.
Claim 8
Dependent Claim
23 words
A complex metallic derivative of claim 1 wherein the metal is selected from the group consisting of cobalt, nickel, copper, iron and zinc.
Claim 9
Dependent Claim
10 words
The complex of claim 7 wherein the metal is zinc.
Claim 10
Dependent Claim
47 words
A composition for retarding the extinction of a response to a conditional retarding avoidance or the disappearance of a taught response or increasing attention, vigilance or memorization comprising an amount of at least one compound of claim 1 sufficient to obtain said effect and a pharmaceutical carrier.
Claim 11
Dependent Claim
11 words
The composition of claim 9 wherein X is the sequence Ala-Ala.
Claim 12
Dependent Claim
10 words
The composition of claim 9 wherein X is sequence Glu-His.
Claim 13
Dependent Claim
22 words
The composition of claim 9 which is selected from the group consisting of the cyclic disulfide (1→6) of N-(cysteinylalanylalanylphenylalanyl-D-lysyl)-cysteine and its acetate.
Claim 14
Dependent Claim
21 words
The composition of claim 9 which is selected from the group consisting of cyclic disulfide (1→4) of N-(cysteinylalanylalanylcysteinyl-D-lysyl)-phenylalanine and its acetate.
Claim 15
Dependent Claim
13 words
The composition of claim 9 which is the cyclic disulfide (1→4) of (N-cysteinylglutamylhistidinylcysteinyl-D-lysyl)-phenylalanine.
Claim 16
Dependent Claim
26 words
A composition of claim 10 which is a metallic complex wherein the metal is selected from the group consisting of cobalt, nickel, copper, iron and zinc.
Claim 17
Dependent Claim
10 words
The composition of claim 9 wherein the metal is zinc.
Claim 18
Dependent Claim
50 words
A method for retarding the extinction of a response to a conditional retarding avoidance or the disappearance of a taught response or increasing attention, vigilance or memorization of warm-blooded animals comprising administering to warm-blooded animals an amount of at least one compound of claim 1 sufficient to obtain said effect.
Claim 19
Dependent Claim
11 words
The method of claim 17 wherein X is the sequence Ala-Ala.
Claim 20
Dependent Claim
11 words
The method of claim 17 wherein X is the sequence Glu-His.
Claim 21
Dependent Claim
24 words
The method of claim 17 wherein the compound is selected from the group consisting of the cyclic disulfide (1→6) of N-(cysteinylalanylalanylphenylalanyl-D-lysyl)-cysteine and its acetate.
Claim 22
Dependent Claim
23 words
The method of claim 17 wherein the compound is selected from the group consisting of cyclic disulfide (1→4) of N-(cysteinylalanylalanylcysteinyl-D-lysyl)-phenylalanine and its acetate.
Claim 23
Dependent Claim
21 words
The method of claim 17 wherein the compound is selected from the group consisting of the cyclic disulfide (1→4) of (N-cysteinylglutamyhistidinylcysteinyl-D-lysyl)-phenylalanine.
Claim 24
Dependent Claim
29 words
The method of claim 17 wherein the compound is a complex metallic derivative wherein the metal is selected from the group consisting of cobalt, nickel, copper, iron and zinc.
Claim 25
Dependent Claim
10 words
The method of claim 23 wherein the metal is zinc.
References Cited (Backward Citations)
GB1429195A
Cited
GB1557076A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-31 | 1987-05-02 | 1987-11-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-31 | 1991-05-02 | 1991-11-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-31 | 1995-05-02 | 1995-11-01 | $7700.00 | Window Closed / Lapsed |